Flow Cytometry

Platelets

Volumn , Issue , 2013, Pages 581-602

  Berny Lang, Michelle A ^a   Frelinger, A L ^a   Barnard, Marc R ^a   Michelson, Alan D ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882669464     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387837-3.00029-8     Document Type: Chapter

References (242)

1. Shattil S.J., Cunningham M., Hoxie J.A. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987, 70:307-315.
2. Michelson A.D., Barnard M.R., Krueger L.A., Frelinger A.L., Furman M.I. Evaluation of platelet function by flow cytometry. Methods 2000, 21:259-270.
3. Michelson A.D., Barnard M.R., Benoit S.E., Mitchell J., Knowles C., Ault K.A. Characterization of platelet binding of blind panel mAb. Leucocyte typing V 1995, 1207-1210. Oxford University Press, Oxford. S.F. Schlocman, L. Boumsell, W. Gilks, J.W. Harlan, T. Kishimoto, C. Morimoto (Eds.).
4. Krueger L.A., Barnard M.R., Frelinger A.L., Furman M.I., Michelson A.D. Immunophenotypic analysis of platelets. Current protocols in cytometry 2002, 6.10.1-6.10.17. John Wiley & Sons, New York. 1st ed. J.P. Robinson, Z. Darzynkiewicz, P.N. Dean, L.G. Dressler, P.S. Rabinovitch, C.C. Stewart (Eds.).
5. Barnard M.R., Krueger L.A., Frelinger A.L., Furman M.I., Michelson A.D. Whole blood analysis of leukocyte-platelet aggregates. Current protocols in cytometry 2003, 6.15.1-6.15.8. John Wiley & Sons, New York. J.P. Robinson, Z. Darzynkiewicz, P.N. Dean, L.G. Dressler, P.S. Rabinovitch, C.C. Stewart (Eds.).
6. Santos M.T., Valles J., Marcus A.J., Safier L.B., Broekman M.J., Islam N., et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest 1991, 87:571-580.
7. LaRosa C.A., Rohrer M.J., Rodino L.J., Benoit S.E., Barnard M.R., Michelson A.D. Human neutrophil cathepsin G is a potent platelet activator. J Vasc Surg 1994, 19:306-319.
8. Michelson A.D., Ellis P.A., Barnard M.R., Matic G.B., Viles A.F., Kestin A.S. Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, ADP or an in vivo wound. Blood 1991, 77:770-779.
9. Abrams C., Shattil S.J. Immunological detection of activated platelets in clinical disorders. Thromb Haemost 1991, 65:467-473.
10. Michelson A.D. Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications. Blood Coagul Fibrinolysis 1994, 5:121-131.
11. Kestin A.S., Ellis P.A., Barnard M.R., Errichetti A., Rosner B.A., Michelson A.D. The effect of strenuous exercise on platelet activation state and reactivity. Circulation 1993, 88:1502-1511.
12. Rajasekhar D., Barnard M.R., Bednarek F.J., A.D.Michelson Platelet hyporeactivity in very low birth weight neonates. Thromb Haemost 1997, 77(5):1002-1007.
13. Psaila B., Bussel J.B., Frelinger A.L., Babula B., Linden M.D., Li Y., et al. Differences in platelet function between patients with acute myeloid leukemia compared to myelodysplasia and equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost 2011, 9:2302-10.
14. Michelson AD, Benoit SE, Barnard MR, MacGregor H, Valeri CR. A panel of platelet mAb for the study of haemostasis and thrombosis in baboons. Leucocyte typing V 1995, 1230-1231. Oxford University Press, Oxford. S.F. Schlossman, L. Boumsell, W. Gilks, J.M. Harlan, T. Kishimoto, C. Morimoto (Eds.).
15. Michelson A.D., Barnard M.R., Hechtman H.B., MacGregor H., Connolly R.J., Loscalzo J., et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 1996, 93:11877-11892.
16. Alugupalli K.R., Michelson A.D., Barnard M.R., Leong J.M. Serial determinations of platelet counts in mice by flow cytometry. Thromb Haemost 2001, 86:668-671.
17. Shattil S.J., Hoxie J.A., Cunningham M., Brass L.F. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. J Biol Chem 1985, 260:11107-11114.
18. Frelinger A.L., Lam S.C., Plow E.F., Smith M.A., Loftus J.C., Ginsberg M.H. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem 1988, 263:12397-12402.
19. Zamarron C., Ginsberg M.H., Plow E.F. Monoclonal antibodies specific for a conformationally altered state of fibrinogen. Thromb Haemost 1990, 64:41-46.
20. Faraday N., Goldschmidt-Clermont P., Dise K., Bray P.F. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med 1994, 123:728-740.
21. Heilmann E., Hynes L.A., Burstein S.A., George J.N., Dale G.L. Fluorescein derivatization of fibrinogen for flow cytometric analysis of fibrinogen binding to platelets. Cytometry 1994, 17:287-293.
22. Michelson A.D., Benoit S.E., Kroll M.H., Li J.-M., Rohrer M.J., Kestin A.S., et al. The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible. Blood 1994, 83:3562-3573.
23. Ruf A., Patscheke H. Flow cytometric detection of activated platelets: comparison of determining shape change, fibrinogen binding, and P-selectin expression. Semin Thromb Hemost 1995, 21(2):146-151.
24. Berger G., Hartwell D.W., Wagner D.D. P-Selectin and platelet clearance. Blood 1998, 92(11):4446-4452.
25. Nishibori M., Cham B., McNicol A., Shalev A., Jain N., Gerrard J.M. The protein CD63 is in platelet dense granules, is deficient in a patient with Hermansky-Pudlak syndrome, and appears identical to granulophysin. J Clin Invest 1993, 91(4):1775-1782.
26. Michelson A.D., Barnard M.R., Krueger L.A., Valeri C.R., Furman M.I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001, 104:1533-1537.
27. Furman M.I., Benoit S.E., Barnard M.R., Valeri C.R., Borbone M.L., Becker R.C., et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998, 31(2):352-358.
28. Peyton B.D., Rohrer M.J., Furman M.I., Barnard M.R., Rodino L.J., Benoit S.E., et al. Patients with venous stasis ulceration have increased monocyte-platelet aggregation. J Vasc Surg 1998, 27:1109-1116.
29. Dasgupta S.K., Guchhait P., Thiagarajan P. Lactadherin binding and phosphatidylserine expression on cell surface-comparison with annexin A5. Transl Res 2006, 148(1):19-25.
30. Furman M.I., Krueger L.A., Frelinger A.L., Barnard M.R., Mascelli M.A., Nakada M.T., et al. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost 2000, 84:492-498.
31. Gilbert G.E., Sims P.J., Wiedmer T., Furie B., Furie B.C., Shattil S.J. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem 1991, 266:17261-17268.
32. Thiagarajan P., Tait J.F. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 1990, 265:17420-17423.
33. Sims P.J., Faioni E.M., Wiedmer T., Shattil S.J. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988, 263:18205-18212.
34. Michelson A.D., Rajasekhar D., Bednarek F.J., Barnard M.R. Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults. Thromb Haemost 2000, 84:689-694.
35. Jy W., Horstman L.L., Jimenez J.J., Ahn Y.S., Biro E., Nieuwland R., et al. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004, 2(10):1842-1851.
36. Lacroix R., Robert S., Poncelet P., Kasthuri R.S., Key N.S., Dignat-George F. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the international society on thrombosis and haemostasis SSC collaborative workshop. J Thromb Haemost 2010, 8(11):2571-2574.
37. Lacroix R., Robert S., Poncelet P., Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost 2010, 36(8):807-818.
38. Mobarrez F., Antovic J., Egberg N., Hansson M., Jorneskog G., Hultenby K., et al. A multicolor flow cytometric assay for measurement of platelet-derived microparticles. Thromb Res 2010, 125(3):e110-e116.
39. Orozco A.F., Lewis D.E. Flow cytometric analysis of circulating microparticles in plasma. Cytometry A 2010, 77(6):502-514.
40. Schwarz U.R., Geiger J., Walter U., Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thrombs Haemost 1999, 82(3):1145-1152.
41. Aleil B., Ravanat C., Cazenave J.P., Rochoux G., Heitz A., Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005, 3(1):85-92.
42. Gurbel P.A., Bliden K.P., Samara W., Yoho J.A., Hayes K., Fissha M.Z., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. Results of the CREST study. J Am Coll Cardiol 2005, 46:1827-1832.
43. Bonello L., Camoin-Jau L., Arques S., Boyer C., Panagides D., Wittenberg O., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008, 51(14):1404-1411.
44. Ault K.A., Rinder H.M., Mitchell J.G., Rinder C.S., Lambrew C.T., Hillman R.S. Correlated measurement of platelet release and aggregation in whole blood. Cytometry 1989, 10:448-455.
45. Abrams C.S., Ellison N., Budzynski A.Z., Shattil S.J. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990, 75:128-138.
46. Kestin A.S., Valeri C.R., Khuri S.F., Loscalzo J., Ellis P.A., MacGregor H., et al. The platelet function defect of cardiopulmonary bypass. Blood 1993, 82:107-117.
47. Michelson A.D., MacGregor H., Barnard M.R., Kestin A.S., Rohrer M.J., Valeri C.R. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost 1994, 71:633-640.
48. Ott I., Neumann F.J., Gawaz M., Schmitt M., Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996, 94(6):1239-1246.
49. Coulter S.A., Cannon C.P., Ault K.A., Antman E.M., Van de W.F., Adgey A.A., et al. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation 2000, 101(23):2690-2695.
50. Schultheiss H.P., Tschoepe D., Esser J., Schwippert B., Roesen P., Nieuwenhuis H.K., et al. Large platelets continue to circulate in an activated state after myocardial infarction. Eur J Clin Invest 1994, 24:243-247.
51. Stellos K., Bigalke B., Stakos D., Henkelmann N., Gawaz M. Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication. J Thromb Haemost 2010, 8(1):205-207.
52. Scharf R.E., Tomer A., Marzec U.M., Teirstein P.S., Ruggeri Z.M., Harker L.A. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscler Thromb 1992, 12:1475-1487.
53. Langford E.J., Brown A.S., Wainwright R.J., de Belder A.J., Thomas M.R., Smith R.E., et al. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet 1994, 344:1458-1460.
54. Langford E.J., Wainwright R.J., Martin J.F. Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Arterioscler Thromb Vasc Biol 1996, 16(1):51-55.
55. Ault K.A., Cannon C.P., Mitchell J., McCahan J., Tracy R.P., Novotny W.F., et al. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial. Thrombolysis in myocardial infarction. J Am Coll Cardiol 1999, 33(3):634-639.
56. Frelinger A.L., Michelson A.D., Wiviott S.D., Trenk D., Neumann F.J., Miller D.L., et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011, 106(2):219-226.
57. Gawaz M., Neumann F.J., Ott I., May A., Schomig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996, 94(3):279-285.
58. Neumann F.J., Gawaz M., Dickfeld T., Wehinger A., Walter H., Blasini R., et al. Antiplatelet effect of ticlopidine after coronary stenting. J Am Coll Cardiol 1997, 29(7):1515-1519.
59. Tschoepe D., Schultheiss H.P., Kolarov P., Schwippert B., Dannehl K., Nieuwenhuis H.K., et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993, 88(1):37-42.
60. Gawaz M., Neumann F.J., Ott I., May A., Rudiger S., Schomig A. Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis. Coron Artery Dis 1997, 8(3-4):121-128.
61. Kabbani S.S., Watkins M.W., Ashikaga T., Terrien E.F., Holoch P.A., Sobel B.E., et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001, 104(2):181-186.
62. Kabbani S.S., Watkins M.W., Ashikaga T., Terrien E.F., Sobel B.E., Schneider D.J. Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. Am J Cardiol 2003, 91(7):876-878.
63. Blindt R., Stellbrink K., de T.A., Muller R., Kiefer P., Yagmur E., et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007, 98(6):1329-1334.
64. Bonello L., Paganelli F., Arpin-Bornet M., Auquier P., Sampol J., Dignat-George F., et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007, 5:1630-1636.
65. Bonello L., Camoin-Jau L., Armero S.C.O., Arques S., Burignat-Bonello C., Giacomoni M., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009, 103:5-10.
66. Bonello L., Tantry U.S., Marcucci R., Blindt R., Angiolillo D.J., Becker R., et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010, 56(12):919-933.
67. Fateh-Moghadam S., Bocksch W., Ruf A., Dickfeld T., Schartl M., Pogatsa-Murray G., et al. Changes in surface expression of platelet membrane glycoproteins and progression of heart transplant vasculopathy. Circulation 2000, 102(8):890-897.
68. Michelson A.D., Furman M.I., Goldschmidt-Clermont P., Mascelli M.A., Hendrix C., Coleman L., et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000, 101(9):1013-1018.
69. Totani L., Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010, 30(12):2357-2361.
70. Kopp C.W., Gremmel T., Steiner S., Seidinger D., Minar E., Maurer G., et al. Platelet-monocyte cross talk and tissue factor expression in stable angina vs. unstable angina/non ST-elevation myocardial infarction. Platelets 2011, 22(7):530-536.
71. Gawaz M., Reininger A., Neumann F.J. Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease. Effects of intravenous magnesium. Thromb Res 1996, 83(5):341-349.
72. Neumann F.J., Marx N., Gawaz M., Brand K., Ott I., Rokitta C., et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997, 95(10):2387-2394.
73. Furman M.I., Barnard M.R., Krueger L.A., Fox M.L., Shilale E.A., Lessard D.M., et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001, 38:1002-1006.
74. Rinder C.S., Bonan J.L., Rinder H.M., Mathew J., Hines R., Smith B.R. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992, 79:1201-1205.
75. Mickelson J.K., Lakkis N.M., Villarreal-Levy G., Hughes B.J., Smith C.W. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?. J Am Coll Cardiol 1996, 28:345-353.
76. Cao Y.J., Wang Y.M., Zhang J., Zeng Y.J., Liu C.F. The effects of antiplatelet agents on platelet-leukocyte aggregations in patients with acute cerebral infarction. J Thromb Thrombolysis 2009, 27(2):233-238.
77. Bigalke B., Lindemann S., Ehlers R., Seizer P., Daub K., Langer H., et al. Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006, 27(18):2165-2169.
78. Bigalke B., Geisler T., Stellos K., Langer H., Daub K., Kremmer E., et al. Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome. Am Heart J 2008, 156(1):193-200.
79. Bigalke B., Haap M., Stellos K., Geisler T., Seizer P., Kremmer E., et al. Platelet glycoprotein VI (GPVI) for early identification of acute coronary syndrome in patients with chest pain. Thromb Res 2010, 125(5):e184-e189.
80. Katopodis J.N., Kolodny L., Jy W., Horstman L.L., De Marchena E.J., Tao J.G., et al. Platelet microparticles and calcium homeostasis in acute coronary ischemias. Am J Hematol 1997, 54(2):95-101.
81. George J.N., Pickett E.B., Saucerman S., McEver R.P., Kunicki T.J., Kieffer N., et al. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986, 78:340-348.
82. Grau A.J., Ruf A., Vogt A., Lichy C., Buggle F., Patscheke H., et al. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost 1998, 80(2):298-301.
83. Zeller J.A., Tschoepe D., Kessler C. Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemost 1999, 81(3):373-377.
84. Meiklejohn D.J., Vickers M.A., Morrison E.R., Dijkhuisen R., Moore I., Urbaniak S.J., et al. In vivo platelet activation in atherothrombotic stroke is not determined by polymorphisms of human platelet glycoprotein IIIa or Ib. Br J Haematol 2001, 112(3):621-631.
85. Yamazaki M., Uchiyama S., Iwata M. Measurement of platelet fibrinogen binding and p-selectin expression by flow cytometry in patients with cerebral infarction. Thromb Res 2001, 104(3):197-205.
86. Cherian P., Hankey G.J., Eikelboom J.W., Thom J., Baker R.I., McQuillan A., et al. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke 2003, 34(9):2132-2137.
87. Yip H.K., Chen S.S., Liu J.S., Chang H.W., Kao Y.F., Lan M.Y., et al. Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. Stroke 2004, 35:1683-1687.
88. McCabe D.J., Harrison P., Mackie I.J., Sidhu P.S., Purdy G., Lawrie A.S., et al. Platelet degranulation and monocyte-platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack. Br J Haematol 2004, 125(6):777-787.
89. Smout J., Dyker A., Cleanthis M., Ford G., Kesteven P., Stansby G. Platelet function following acute cerebral ischemia. Angiology 2009, 60(3):362-369.
90. Tsai N.W., Chang W.N., Shaw C.F., Jan C.R., Chang H.W., Huang C.R., et al. Levels and value of platelet activation markers in different subtypes of acute non-cardio-embolic ischemic stroke. Thromb Res 2009, 124(2):213-218.
91. Marquardt L., Ruf A., Mansmann U., Winter R., Schuler M., Buggle F., et al. Course of platelet activation markers after ischemic stroke. Stroke 2002, 33(11):2570-2574.
92. Htun P., Fateh-Moghadam S., Tomandl B., Handschu R., Klinger K., Stellos K., et al. Course of platelet activation and platelet-leukocyte interaction in cerebrovascular ischemia. Stroke 2006, 37(9):2283-2287.
93. Minamino T., Kitakaze M., Sanada S., Asanuama H., Kurotobi T., Koretsune Y., et al. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation 1998, 98(17):1721-1727.
94. Bigalke B., Stellos K., Geisler T., Kremmer E., Seizer P., May A.E., et al. Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke. Eur J Neurol 2010, 17(1):111-117.
95. Lee Y.J., Jy W., Horstman L.L., Janania J., Reyes Y., Kelley R.E., et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thrombos Res 1994, 72(4):295-304.
96. Geiser T., Sturzenegger M., Genewein U., Haeberli A., Beer J.H. Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves. Stroke 1998, 29(9):1770-1777.
97. Fateh-Moghadam S., Li Z., Ersel S., Reuter T., Htun P., Plöckinger U., et al. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arterioscler Thromb Vasc Biol 2005, 25:1299-1303.
98. Koyama H., Maeno T., Fukumoto S., Shoji T., Yamane T., Yokoyama H., et al. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation 2003, 108(5):524-529.
99. Zeiger F., Stephan S., Hoheisel G., Pfeiffer D., Ruehlmann C., Koksch M. P-Selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease. Blood Coagul Fibrinolysis 2000, 11(8):723-728.
100. Cassar K., Bachoo P., Ford I., Greaves M., Brittenden J. Platelet activation is increased in peripheral arterial disease. J Vasc Surg 2003 July, 38(1):99-103.
101. Rajagopalan S., Mckay I., Ford I., Bachoo P., Greaves M., Brittenden J. Platelet activation increases with the severity of peripheral arterial disease: implications for clinical management. J Vasc Surg 2007, 46(3):485-490.
102. Esposito C.J., Popescu W.M., Rinder H.M., Schwartz J.J., Smith B.R., Rinder C.S. Increased leukocyte-platelet adhesion in patients with graft occlusion after peripheral vascular surgery. Thromb Haemost 2003, 90(6):1128-1134.
103. Powell C.C., Rohrer M.J., Barnard M.R., Peyton B.D., Furman M.I., Michelson A.D. Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation. J Vasc Surg 1999, 30(5):844-851.
104. Rohrer M.J., Claytor R.B., Garnette C.S.C., Powell C.C., Barnard M.R., Furman M.I., et al. Platelet-monocyte aggregates in patients with chronic venous insufficiency remain elevated following correction of reflux. Cardiovasc Surg 2002, 10:464-469.
105. Tschoepe D., Roesen P., Esser J., Schwippert B., Nieuwenhuis H.K., Kehrel B., et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991, 17(4):433-438.
106. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Sabate M., Jimenez-Quevedo P., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005, 54(8):2430-2435.
107. Hu H., Li N., Yngen M., Ostenson C.G., Wallen N.H., Hjemdahl P. Enhanced leukocyte-platelet cross-talk in type 1 diabetes mellitus: relationship to microangiopathy. J Thromb Haemost 2004, 2(1):58-64.
108. Elalamy I., Chakroun T., Gerotziafas G.T., Petropoulou A., Robert F., Karroum A., et al. Circulating platelet-leukocyte aggregates: a marker of microvascular injury in diabetic patients. Thromb Res 2008, 121(6):843-848.
109. Serebruany V.L., Malinin A., Ong S., Atar D. Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. J Thromb Thrombolysis 2008, 25(2):207-213.
110. Choudhury A., Chung I., Blann A.D., Lip G.Y. Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to P-selectin and antithrombotic therapy. Chest 2007, 131(3):809-815.
111. Hammwohner M., Ittenson A., Dierkes J., Bukowska A., Klein H.U., Lendeckel U., et al. Platelet expression of CD40/CD40 ligand and its relation to inflammatory markers and adhesion molecules in patients with atrial fibrillation. Exp Biol Med (Maywood) 2007, 232(4):581-589.
112. Choudhury A., Chung I., Panja N., Patel J., Lip G.Y. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention. Chest 2008, 134(3):574-581.
113. O'Sullivan B.P., Linden M.D., Frelinger A.L., Barnard M.R., Spencer-Manzon M., Morris J.E., et al. Platelet activation in cystic fibrosis. Blood 2005, 105(12):4635-4641.
114. Janes S.L., Goodall A.H. Flow cytometric detection of circulating activated platelets and platelet hyper-responsiveness in pre-eclampsia and pregnancy. Clin Sci 1994, 86:731-739.
115. Konijnenberg A., van der Post J.A., Mol B.W., Schaap M.C., Lazarov R., Bleker O.P., et al. Can flow cytometric detection of platelet activation early in pregnancy predict the occurrence of preeclampsia? A prospective study. Am J Obstet Gynecol 1997, 177(2):434-442.
116. Trudinger B., Song J.Z., Wu Z.H., Wang J. Placental insufficiency is characterized by platelet activation in the fetus. Obstet Gynecol 2003, 101(5:Pt 1):975-981.
117. Zeller J.A., Frahm K., Baron R., Stingele R., Deuschl G. Platelet-leukocyte interaction and platelet activation in migraine: a link to ischemic stroke?. J Neurol Neurosurg Psychiatry 2004, 75(7):984-987.
118. Sirolli V., Ballone E., Garofalo D., Merciaro G., Settefrati N., Di Mascio R., et al. Platelet activation markers in patients with nephrotic syndrome. A comparative study of different platelet function tests. Nephron 2002, 91(3):424-430.
119. Gawaz M.P., Mujais S.K., Schmidt B., Blumenstein M., Gurland H.J. Platelet-leukocyte aggregates during hemodialysis: effect of membrane type. Artif Organs 1999, 23(1):29-36.
120. Wun T., Cordoba M., Rangaswami A., Cheung A.W., Paglieroni T. Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol 2002, 24(2):81-88.
121. Ogura H., Kawasaki T., Tanaka H., Koh T., Tanaka R., Ozeki Y., et al. Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma-Inj Infect Crit Care 2001, 50(5):801-809.
122. Gawaz M., Dickfeld T., Bogner C., Fateh-Moghadam S., Neumann F.J. Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med 1997, 23(4):379-385.
123. Russwurm S., Vickers J., Meier-Hellmann A., Spangenberg P., Bredle D., Reinhart K., et al. Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 2002, 17(4):263-268.
124. Joseph J.E., Harrison P., Mackie I.J., Isenberg D.A., Machin S.J. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001, 115(2):451-459.
125. Bunescu A., Seideman P., Lenkei R., Levin K., Egberg N. Enhanced fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J Rheumatol 2004, 31(12):2347-2355.
126. Danese S., de la M.C., Sturm A., Vogel J.D., West G.A., Strong S.A., et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterol 2003, 124(5):1249-1264.
127. Jensen M.K., de Nully B.P., Lund B.V., Nielsen O.J., Hasselbalch H.C. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001, 66(3):143-151.
128. Villmow T., Kemkes-Matthes B., Matzdorff A.C. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res 2002, 108(2-3):139-145.
129. Sevush S., Jy W., Horstman L.L., Mao W.W., Kolodny L., Ahn Y.S. Platelet activation in Alzheimer disease. Arch Neurol 1998, 55(4):530-536.
130. Vanacore R., Guida C., Urciuoli P., Mazzoni A., Bianco I., Urbani L., et al. High levels of circulating monocyte-platelet aggregates can predict rejection episodes after orthotopic liver transplantation. Transplantation Proc 2003, 35(3):1019.
131. Ando M., Iwata A., Ozeki Y., Tsuchiya K., Akiba T., Nihei H. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 2002, 62(5):1757-1763.
132. Bednarek F.J., Bean S., Barnard M.R., Frelinger A.L., Michelson A.D. The platelet hyporeactivity of extremely low birth weight neonates is age-dependent. Thromb Res 2009, 124(1):42-45.
133. Setzer E.S., Webb I.B., Wassenaar J.W., Reeder J.D., Mehta P.S., Eitzman D.V. Platelet dysfunction and coagulopathy in intraventricular hemorrhage in the premature infant. J Pediatr 1982, 100:599-605.
134. Leinoe E.B., Hoffmann M.H., Kjaersgaard E., Nielsen J.D., Bergmann O.J., Klausen T.W., et al. Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function. Br J Haematol 2005, 128(4):526-532.
135. Michelson A.D. Flow cytometric analysis of platelet surface glycoproteins: phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia. J Lab Clin Med 1987, 110:346-354.
136. Jennings L.K., Ashmun R.A., Wang W.C., Dockter M.E. Analysis of human platelet glycoproteins IIb-IIIa and Glanzmann's thrombasthenia in whole blood by flow cytometry. Blood 1986, 68:173-179.
137. Ginsberg M.H., Frelinger A.L., Lam S.C., Forsyth J., McMillan R., Plow E.F., et al. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies. Blood 1990, 76:2017-2023.
138. Lages B., Shattil S.J., Bainton D.F., Weiss H.J. Decreased content and surface expression of alpha-granule membrane protein GMP-140 in one of two types of platelet alpha delta storage pool deficiency. J Clin Invest 1991, 87:919-929.
139. Sims P.J., Wiedmer T., Esmon C.T., Weiss H.J., Shattil S.J. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989, 264:17049-17057.
140. Giannini S., Cecchetti L., Mezzasoma A.M., Gresele P. Diagnosis of platelet-type von Willebrand disease by flow cytometry. Haematologica 2010, 95(6):1021-1024.
141. Nieuwenhuis H.K., Akkerman J.W., Sixma J.J. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood 1987, 70:620-623.
142. Lorez H.P., Richards J.G., Da Prada M., Picotti G.B., Pareti F.I., Capitanio A., et al. Storage pool disease: comparative fluorescence microscopical, cytochemical and biochemical studies on amine-storing organelles of human blood platelets. Br J Haematol 1979, 43:297-305.
143. Gordon N., Thom J., Cole C., Baker R. Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry. Br J Haematol 1995, 89:117-123.
144. Wall J.E., Buijs-Wilts M., Arnold J.T., Wang W., White M.M., Jennings L.K., et al. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol 1995, 89:380-385.
145. Gawaz M.P., Bogner C., Gurland H.J. Flow-cytometric analysis of mepacrine-labelled platelets in patients with end-stage renal failure. Haemostasis 1993, 23:284-292.
146. Maurer-Spurej E., Dyker K., Gahl W.A., Devine D.V. A novel immunocytochemical assay for the detection of serotonin in platelets. Br J Haematol 2002, 116(3):604-611.
147. Maurer-Spurej E., Pittendreigh C., Wu J.K. Diagnosing platelet delta-storage pool disease in children by flow cytometry. Am J Clin Pathol 2007, 127(4):626-632.
148. Warkentin T.E., Hayward C.P., Boshkov L.K., Santos A.V., Sheppard J.A., Bode A.P., et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994, 84:3691-3699.
149. Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 1997, 98(3):648-656.
150. Mullier F., Bailly N., Cornet Y., Dubuc E., Robert S., Osselaer J.C., et al. Contribution of platelet microparticles generation assay to the diagnosis of type II heparin-induced thrombocytopenia. Thromb Haemost 2010, 103(6):1277-1281.
151. Gobbi G., Mirandola P., Tazzari P.L., Talarico E., Caimi L., Martini G., et al. New laboratory test in flow cytometry for the combined analysis of serologic and cellular parameters in the diagnosis of heparin-induced thrombocytopenia. Cytometry Part B (Clin Cytometry) 2004, 58(1):32-38.
152. Small D.S., Payne C.D., Kothare P., Yuen E., Natanegara F., Teng L.M., et al. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30mg and clopidogrel 300mg in healthy Chinese and white volunteers: an open-label trial. Clin Ther 2010, 32(2):365-379.
153. Wiviott S.D., Trenk D., Frelinger A.L., O'Donoghue M., Neumann F.J., Michelson A.D., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007, 116(25):2923-2932.
154. Michelson A.D., Frelinger A.L., Braunwald E., Downey W.E., Angiolillo D.J., Xenopoulos N.P., et al. Pharmacodynamic assessment of platelet inhibition by prasugrel versus clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009, 30:1753-1763.
155. Konstantopoulos K., Kamat S.G., Schafer A.I., Banez E.I., Jordan R., Kleiman N.S., et al. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation 1995, 91:1427-1431.
156. Gawaz M., Ruf A., Neumann F.-J., Pogatsa-Murray G., Dickfeld T., Zohlnhofer D., et al. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost 1998, 80:994-1001.
157. Quinn M., Deering A., Stewart M., Cox D., Foley B., Fitzgerald D. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. Circulation 1999, 99(17):2231-2238.
158. Hezard N., Metz D., Nazeyrollas P., Nguyen P., Simon G., Daliphard S., et al. Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA. Thromb Haemost 1999, 81(6):869-873.
159. Liu C.Z., Hur B.T., Huang T.F. Measurement of glycoprotein IIb/IIIa blockade by flow cytometry with fluorescein isothiocyanate-conjugated crotavirin, a member of disintegrins. Thromb Haemost 1996, 76(4):585-591.
160. Tsao P.W., Bozarth J.M., Jackson S.A., Forsythe M.S., Flint S.K., Mousa S.A. Platelet GPIIb/IIIa receptor occupancy studies using a novel fluoresceinated cyclic Arg-Gly-Asp peptide. Thromb Res 1995, 77(6):543-556.
161. Wittig K., Rothe G., Schmitz G. Inhibition of fibrinogen binding and surface recruitment of GpIIb/IIIa as dose-dependent effects of the RGD-mimetic MK-852. Thromb Haemost 1998, 79(3):625-630.
162. Mascelli M.A., Lance E.T., Damaraju L., Wagner C.L., Weisman H.F., et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998, 97(17):1680-1688.
163. Peter K., Kohler B., Straub A., Ruef J., Moser M., Nordt T., et al. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. Circulation 2000, 102(13):1490-1496.
164. Jennings L.K., White M.M. Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors. Am Heart J 1998, 135(5 Pt 2 Su):S179-S183.
165. Frelinger A.L., Furman M.I., Linden M.D., Li Y., Fox M.L., Barnard M.R., et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006, 113(25):2888-2896.
166. Frelinger A.L., Li Y., Linden M.D., Barnard M.R., Fox M.L., Christie D.J., et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009, 120(25):2586-2596.
167. Kienast J., Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 1990, 75:116-121.
168. Bonan J.L., Rinder H.M., Smith B.R. Determination of the percentage of thiazole orange (TO)-positive, reticulated platelets using autologous erythrocyte TO fluorescence as an internal standard. Cytometry 1993, 14:690-694.
169. Matic G.B., Chapman E.S., Zaiss M., Rothe G., Schmitz G. Whole blood analysis of reticulated platelets: improvements of detection and assay stability. Cytometry 1998, 34(5):229-234.
170. Ault K.A., Rinder H.M., Mitchell J., Carmody M.B., Vary C.P., Hillman R.S. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 1992, 98:637-646.
171. Jimenez M.M., Guedan M.J., Martin L.M., Campos J.A., Martinez I.R., Vilella C.T. Measurement of reticulated platelets by simple flow cytometry: an indirect thrombocytopoietic marker. Eur J Intern Med 2006, 17(8):541-544.
172. Romp K.G., Peters W.P., Hoffman M. Reticulated platelet counts in patients undergoing autologous bone marrow transplantation: an aid in assessing marrow recovery. Am J Hematol 1994, 46:319-324.
173. Rinder H.M., Schuster J.E., Rinder C.S., Wang C., Schweidler H.J., Smith B.R. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood 1998, 91(4):1288-1294.
174. Robinson M.S., Mackie I.J., Khair K., Liesner R., Goodall A.H., Savidge G.F., et al. Flow cytometric analysis of reticulated platelets: evidence for a large proportion of non-specific labelling of dense granules by fluorescent dyes. Br J Haematol 1998, 100(2):351-357.
175. Balduini C.L., Noris P., Spedini P., Belletti S., Zambelli A., Da Prada G.A. Relationship between size and thiazole orange fluorescence of platelets in patients undergoing high-dose chemotherapy. Br J Haematol 1999, 106(1):202-207.
176. Robinson M., Machin S., Mackie I., Harrison P. In vivo biotinylation studies: specificity of labelling of reticulated platelets by thiazole orange and mepacrine. Br J Haematol 2000, 108(4):859-864.
177. Briggs C., Kunka S., Hart D., Oguni S., Machin S.J. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol 2004, 126(1):93-99.
178. Dumont L.J., VandenBroeke T., Ault K.A. Platelet surface P-selectin measurements in platelet preparations: an international collaborative study. Biomedical excellence for safer transfusion (BEST) working party of the international society of blood transfusion (ISBT). Transfusion Med Rev 1999, 13(1):31-42.
179. Krishnamurti C., Maglasang P., Rothwell S.W. Reduction of blood loss by infusion of human platelets in a rabbit kidney injury model. Transfusion 1999, 39(9):967-974.
180. Holme S., Sweeney J.D., Sawyer S., Elfath M.D. The expression of P-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability. Transfusion 1997, 37(1):12-17.
181. Cardigan R., Turner C., Harrison P. Current methods of assessing platelet function: relevance to transfusion medicine. Vox Sang 2005, 88(3):153-163.
182. Garner S.F., Jones C.I., Stephens J., Burns P., Walton J., Bernard A., et al. Apheresis donors and platelet function: inherent platelet responsiveness influences platelet quality. Transfusion 2008, 48(4):673-680.
183. Forsberg B., Jacobsson S., Stockelberg D., Kutti J., Rydberg L., Wadenvik H. The platelet-specific alloantigen PlA1 (HPA-1a): a comparison of flow cytometric immunophenotyping and genotyping using polymerase chain reaction and restriction fragment length polymorphism in a Swedish blood donor population. Transfusion 1995, 35:241-246.
184. Marshall L.R., Brogden F.E., Roper T.S., Barr A.L. Antenatal platelet antibody testing by flow cytometry-results of a pilot study. Transfusion 1994, 34:961-965.
185. Gates K., MacPherson B.R. Retrospective evaluation of flow cytometry as a platelet crossmatching procedure. Cytometry 1994, 18:123-128.
186. Sayed D., Bakry R., El-Sharkawy N., Zahran A., Khalaf M.R. Flow cytometric platelet cross-matching to predict platelet transfusion in acute leukemia. J Clin Apher 2011, 26(1):23-28.
187. Holme S., Heaton A., Kunchuba A., Hartman P. Increased levels of platelet associated IgG in patients with thrombocytopenia are not confined to any particular size class of platelets. Br J Haematol 1988, 68:431-436.
188. Tomer A., Koziol J., McMillan R. Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated autoantibodies against platelet-specific receptors. J Thromb Haemost 2005, 3(1):74-78.
189. Huh H.J., Park C.J., Kim S.W., Han S.H., Jang S., Chi H.S. Flow cytometric detection of platelet-associated immunoglobulin in patients with immune thrombocytopenic purpura and nonimmune thrombocytopenia. Ann Clin Lab Sci 2009, 39(3):283-288.
190. Rosenfeld C.S., Bodensteiner D.C. Detection of platelet alloantibodies by flow cytometry. Characterization and clinical significance. Am J Clin Pathol 1986, 85:207-212.
191. Hagenstrom H., Schlenke P., Hennig H., Kirchner H., Kluter H. Quantification of platelet-associated IgG for differential diagnosis of patients with thrombocytopenia. Thromb Haemost 2000, 84(5):779-783.
192. Hezard N., Simon G., Mace C., Jallu V., Kaplan C., Nguyen P. Is flow cytometry accurate enough to screen platelet autoantibodies?. Transfusion 2008, 48(3):513-518.
193. Liu X.G., Li J.L., Qin P., Ren J., Ma S.H., Sun L., et al. Determination of platelet-bound glycoprotein-specific autoantibodies by flow cytometric immunobead assay in primary immune thrombocytopenia. Eur J Haematol 2011, 86(4):339-346.
194. Harrison P., Ault K.A., Chapman S., Charie L., Davis B., Fujimoto K., et al. An interlaboratory study of a candidate reference method for platelet counting. Am J Clin Pathol 2001, 115(3):448-459.
195. International council for standardization in haematology expert panel on cytometry, international society of laboratory hematology task force on platelet counting. Platelet counting by the RBC/platelet ratio method. A reference method. Am J Clin Pathol 2001 March; 115(3):460-464.
196. Peng J., Friese P., Heilmann E., George J.N., Burstein S.A., Dale G.L. Aged platelets have an impaired response to thrombin as quantitated by P-selectin expression. Blood 1994, 83:161-166.
197. Heilmann E., Friese P., Anderson S., George J.N., Hanson S.R., Burstein S.A., et al. Biotinylated platelets: a new approach to the measurement of platelet life span. Br J Haematol 1993, 85:729-735.
198. Heilmann E., Hynes L.A., Friese P., George J.N., Burstein S.A., Dale G.L. Dog platelets accumulate intracellular fibrinogen as they age. J Cell Physiol 1994, 161:23-30.
199. Dale G.L., Friese P., Hynes L.A., Burstein S.A. Demonstration that thiazole-orange-positive platelets in the dog are less than 24 hours old. Blood 1995, 85:1822-1825.
200. Dale G.L., Wolf R.F., Hynes L.A., Friese P., Burstein S.A. Quantitation of platelet life span in splenectomized dogs. Exp Hematol 1996, 24:518-523.
201. Male C., Koren D., Eichelberger B., Kaufmann K., Panzer S. Monitoring survival and function of transfused platelets in Glanzmann thrombasthenia by flow cytometry and thrombelastography. Vox Sang 2006, 91(2):174-177.
202. Panzer S., Eichelberger B., Koren D., Kaufmann K., Male C. Monitoring survival and function of transfused platelets in Bernard-Soulier syndrome by flow cytometry and a cone and plate(let) analyzer (Impact-R). Transfusion 2007, 47(1):103-106.
203. Cesar J.M., Vecino A.M. Survival and function of transfused platelets. Studies in two patients with congenital deficiencies of platelet membrane glycoproteins. Platelets 2009, 20(3):158-162.
204. Hughes D.L., Evans G., Metcalfe P., Goodall A.H., Williamson L.M. Tracking and characterisation of transfused platelets by two colour, whole blood flow cytometry. Br J Haematol 2005, 130(5):791-794.
205. Celi A., Pellegrini G., Lorenzet R., De Blasi A., Ready N., Furie B.C., et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A 1994, 91:8767-8771.
206. Evangelista V., Manarini S., Rotondo S., Martelli N., Polischuk R., McGregor J.L., et al. Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: evidence of adhesion cascade and cross talk between P-selectin and the beta 2 integrin CD11b/CD18. Blood 1996, 88(11):4183-4194.
207. Evangelista V., Manarini S., Sideri R., Rotondo S., Martelli N., Piccoli A., et al. Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule. Blood 1999, 93(3):876-885.
208. Altieri D.C., Edgington T.S. A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1). J Immunol 1988, 141(8):2656-2660.
209. Hogg N., Stewart M.P., Scarth S.L., Newton R., Shaw J.M., Law S.K., et al. A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins Mac-1 and LFA-1. J Clin Invest 1999, 103(1):97-106.
210. Altieri D.C., Morrissey J.H., Edgington T.S. Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci U S A 1988, 85(20):7462-7466.
211. Altieri D.C., Edgington T.S. The saturable high affinity association of factor X to ADP-stimulated monocytes defines a novel function of the Mac-1 receptor. J Biol Chem 1988, 263(15):7007-7015.
212. Altieri D.C., Bader R., Mannucci P.M., Edgington T.S. Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol 1988, 107(5):1893-1900.
213. Rauch U., Bonderman D., Bohrmann B., Badimon J.J., Himber J., Riederer M.A., et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000, 96(1):170-175.
214. Barnard M.R., Linden M.D., Frelinger A.L., Li Y., Fox M.L., Furman M.I., et al. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost 2005, 3:2563-2570.
215. Oda A., Daley J.F., Cabral C., Kang J.H., Smith M., Salzman E.W. Heterogeneity in filamentous actin content among individual human blood platelets. Blood 1992, 79:920-927.
216. LaRosa C.A., Rohrer M.J., Benoit S.E., Barnard M.R., Michelson A.D. Neutrophil cathepsin G modulates the platelet surface expression of the glycoprotein (GP) Ib-IX complex by proteolysis of the von Willebrand factor binding site on GPIbα and by a cytoskeletal-mediated redistribution of the remainder of the complex. Blood 1994, 84:158-168.
217. 2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost 2010, 8(2):331-340.
218. do Ceu Monteiro M., Sansonetty F., Goncalves M.J., O'Connor J.E. Flow cytometric kinetic assay of calcium mobilization in whole blood platelets using Fluo-3 and CD41. Cytometry 1999, 35(4):302-310.
219. Labios M., Martinez M., Gabriel F., Guiral V., Ruiz-Aja S., Aznar J. Cytoplasmic free calcium mobilization in platelets, expression of P-selectin, phosphatidylserine, and microparticle formation, measured by whole blood flow cytometry, in hypertensive patients. Effect of doxazosin GITS. Thromb Res 2006, 117(4):403-409.
220. Sims P.J., Ginsberg M.H., Plow E.F., Shattil S.J. Effect of platelet activation on the conformation of the plasma membrane glycoprotein IIb-IIIa complex. J Biol Chem 1991, 266(12):7345-7352.
221. Koksch M., Rothe G., Kiefel V., Schmitz G. Fluorescence resonance energy transfer as a new method for the epitope-specific characterization of anti-platelet antibodies. J Immunol Methods 1995, 187:53-67.
222. Freedman J.E., Loscalzo J., Barnard M.R., Alpert C., Keaney J.F., Michelson A.D. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997, 100(2):350-356.
223. Alugupalli K.R., Michelson A.D., Barnard M.R., Robbins D., Coburn J., Baker E.K., et al. Platelet activation by a relapsing fever spirochaete results in enhanced bacterium-platelet interaction via integrin alphaIIbbeta3 activation. Mol Microbiol 2001, 39(2):330-340.
224. Yeh J.J., Tsai S., Wu D.C., Wu J.Y., Liu T.C., Chen A. P-selectin-dependent platelet aggregation and apoptosis may explain the decrease in platelet count during Helicobacter pylori infection. Blood 2010, 115(21):4247-4253.
225. Frelinger A.L., Cohen I., Plow E.F., Smith M.A., Roberts J., Lam S.C., et al. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem 1990, 265:6346-6352.
226. Gralnick H.R., Williams S.B., McKeown L., Shafer B., Connaghan G.D., Hansmann K., et al. Endogenous platelet fibrinogen: its modulation after surface expression is related to size-selective access to and conformational changes in the bound fibrinogen. Br J Haematol 1992, 80:347-357.
227. Schoolmeester A., Vanhoorelbeke K., Katsutani S., Depraetere H., Feys H.B., Heemskerk J.M., et al. Monoclonal antibody IAC-1 is specific for activated alpha2beta1 and binds to amino acids 199 to 201 of the integrin alpha2 I-domain. Blood 2004, 104(2):390-396.
228. Larsen E., Celi A., Gilbert G.E., Furie B.C., Erban J.K., Bonfanti R., et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989, 59:305-312.
229. Stenberg P.E., McEver R.P., Shuman M.A., Jacques Y.V., Bainton D.F. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985, 101:880-886.
230. Carmody M.W., Ault K.A., Mitchell J.G., Rote N.S., Ng A.K. Production of monoclonal antibodies specific for platelet activation antigens and their use in evaluating platelet function. Hybridoma 1990, 9(6):631-641.
231. Metzelaar M.J., Heijnen H.F., Sixma J.J., Nieuwenhuis H.K. Identification of a 33-Kd protein associated with the alpha-granule membrane (GMP-33) that is expressed on the surface of activated platelets. Blood 1992, 79(2):372-379.
232. Damas C., Vink T., Nieuwenhuis H.K., Sixma J.J. The 33-kDa platelet alpha-granule membrane protein (GMP-33) is an N-terminal proteolytic fragment of thrombospondin. Thromb Haemost 2001, 86(3):887-893.
233. Nieuwenhuis H.K., van Oosterhout J.J., Rozemuller E., van Iwaarden F., Sixma J.J. Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. Blood 1987, 70:838-845.
234. Febbraio M., Silverstein R.L. Identification and characterization of LAMP-1 as an activation-dependent platelet surface glycoprotein. J Biol Chem 1990, 265:18531-18537.
235. Silverstein R.L., Febbraio M. Identification of lysosome-associated membrane protein-2 as an activation-dependent platelet surface glycoprotein. Blood 1992, 80(6):1470-1475.
236. Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391(6667):591-594.
237. Chen M., Kakutani M., Naruko T., Ueda M., Narumiya S., Masaki T., et al. Activation-dependent surface expression of LOX-1 in human platelets. Biochem Biophys Res Comm 2001, 282(1):153-158.
238. Boukerche H., McGregor J.L. Characterization of an anti-thrombospondin monoclonal antibody (P8) that inhibits human blood platelet functions. Normal binding of P8 to thrombin-activated Glanzmann thrombasthenic platelets. Eur J Biochem 1988, 171:383-392.
239. Aiken M.L., Ginsberg M.H., Plow E.F. Mechanisms for expression of thrombospondin on the platelet cell surface. Semin Thromb Hemost 1987, 13:307-316.
240. Hayward C.P., Smith J.W., Horsewood P., Warkentin T.E., Kelton J.G. p-155, a multimeric platelet protein that is expressed on activated platelets. J Biol Chem 1991, 266:7114-7120.
241. Hayward C.P., Bainton D.F., Smith J.W., Horsewood P., Stead R.H., Podor T.J., et al. Multimerin is found in the alpha-granules of resting platelets and is synthesized by a megakaryocytic cell line. J Clin Invest 1993, 91:2630-2639.
242. Holme P.A., Brosstad F., Solum N.O. Platelet-derived microvesicles and activated platelets express factor Xa activity. Blood Coagul Fibrinolysis 1995, 6(4):302-310.